As we’ve written before, artificial intelligence (AI) offers many opportunities for advancing cancer research. Today, we examine a promising new ultrasound-reading AI. Recently approved by the FDA.
From Koios Medical: A Promising New Ultrasound-Reading AI
This represents an exciting application. As reported by Andrea Park for Fierce Healthcare:
In the grand tradition of the inquisitive Greek titan that it’s named for, Koios Medical asks big questions of current medical practices. Then, it develops the advanced artificial intelligence technology to answer them. Its flagship product is Koios DS. An AI-powered software platform that analyzes ultrasound images to help diagnose both breast and thyroid cancer. Combined, the two cancers comprise 375,000 diagnoses in the U.S. each year. With more than 2.2 million biopsies of breast and thyroid tissue performed annually. The software is newly cleared by the FDA. Only a few months after it received the agency’s breakthrough device designation in April.
The Koios DS AI algorithms compare ultrasounds to a compendium of hundreds of thousands of previous images with confirmed diagnoses. Collected from 48 sites around the world. The resulting analysis takes approximately two seconds to complete. Thus, ensuring that clinicians make an accurate diagnosis and begin cancer treatment as quickly as possible.
“The loss of life globally to cancers found too late, or misdiagnosed, is tragic. When combined with the millions wasted on avoidable procedures, we feel compelled to relentlessly innovate. Thereby building powerful AI models directly into easy-to-use software,” says CEO Chad McClennan. “This new FDA clearance means physicians will save tens of thousands of lives. While freeing precious time and resources.”
To read more, click the image.
